Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Antibody-dependent cellular phagocytosis in antiviral immune responses
Antiviral activities of antibodies may either be dependent only on interactions between the
antibody and cognate antigen, as in binding and neutralization of an infectious virion, or …
antibody and cognate antigen, as in binding and neutralization of an infectious virion, or …
HIV prevention transformed: the new prevention research agenda
We have entered a new era in HIV prevention whereby priorities have expanded from
biomedical discovery to include implementation, effectiveness, and the effect of combination …
biomedical discovery to include implementation, effectiveness, and the effect of combination …
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing …
A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-
1) vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One …
1) vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One …
Immune-correlates analysis of an HIV-1 vaccine efficacy trial
Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
Analysis of correlates of risk of infection in the RV144 HIV-1 vaccine efficacy trial
demonstrated that plasma IgG against the HIV-1 envelope (Env) variable region 1 and 2 …
demonstrated that plasma IgG against the HIV-1 envelope (Env) variable region 1 and 2 …
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with …
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with …
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
ABSTRACT The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated
efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the …
efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the …
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have
typically shown post-infection virological control, but protection against acquisition of …
typically shown post-infection virological control, but protection against acquisition of …
A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
Ongoing severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) vaccine
development is focused on identifying stable, cost-effective, and accessible candidates for …
development is focused on identifying stable, cost-effective, and accessible candidates for …
[HTML][HTML] Vaccine-induced protection from homologous tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers
Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …